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Background: This study explored the psychometric properties (internal consistency, construct validity,
discriminative ability) of the Juniper Mini Asthma Quality of Life Questionnaire (Mini AQLQ-J) and the Sydney
Asthma Quality of Life Questionnaire (AQLQ-S).
Methods: One hundred fourty-six adults (18–45 years) with asthma requiring regular inhaled corticosteroids were
recruited to a trial of written emotional disclosure. Correlational analyses were performed to understand the
relationship of the two measures with each other, with symptoms, lung function, asthma control, asthma bother
and generic quality of life. Median quality of life scores were compared according to gender, health care usage and
levels of asthma severity.
Results: AQLQ-J and AQLQ-S total scores correlated strongly with each other (rho=−0.80) and moderately with the
EuroQol Current Health Status Scale (AQLQ-J: rho= 0.35; AQLQ-S: rho=−0.40). Domain score correlations between
AQLQ-J and AQLQ-S were mostly moderate (0.50 < rho< 0.80).
Both QoL measures were significantly correlated with symptom score. Correlations with the symptom score asthma
module (AQLQ-J: rho= −0.69; AQLQ-S: rho= 0.50) were stronger compared with the total symptom score and the
symptom score rhinitis module (AQLQ-J: rho=−0.41; AQLQ-S: rho =0.31).
Neither QoL measure was significantly correlated with FEV1, % predicted at the total or the domain level.
Total scores of both measures were significantly correlated with subjective asthma control (AQLQ-J: rho= 0.68;
AQLQ-S: rho=−0.61) and asthma bother (AQLQ-J: rho=−0.73; AQLQ-M: rho= 0.73).
Total AQLQ-J score and total AQLQ-S score were significantly associated with perceived asthma severity (AQLQ-J:
p=0.004, AQLQ-S: p=0.002) and having visited a GP in the past four months (AQLQ-J: p=0.003, AQLQ-S: p=0.002).
Conclusions: This study provides further evidence for the validity of the AQLQ-J and the AQLQ-S in a British
population of adult patients with asthma managed in primary care. Correlations with lung function parameters
were weak or absent. Correlations with generic quality of life were moderate, those with asthma symptoms, asthma
control and asthma bother were strong. Both measures are able to discriminate between levels of asthma severity
and health care usage.* Correspondence: c.apfelbacher@bsms.ac.uk
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Patient reported outcome measures (PROMs) have
gained importance in clinical trials, epidemiological sur-
veys, audit and clinical practice. ‘PROM’ is an umbrella
term proposed by the US Food and Drug Administration
(FDA) denoting the “measurement of any aspect of a
patient’s health status that comes directly from the pa-
tient (i.e. without the interpretation of the patient’s
responses by a physician or anyone else)” [1]. PROMs
are a means of quantifying qualitative information re-
quiring careful consideration in their development [2].
Health-related quality of life (HrQoL) is among the
most important patient assessed health outcomes but is
also referred to as health status, perceived health or sim-
ply ‘quality of life’ [3]. No single concept has been uni-
versally adopted [1,4,5].
For adults with asthma, a variety of health related
quality of life (HrQoL) measures are in use. A recent re-
view identified six commonly used questionnaires and
concluded that the measures differ substantially in a
number of aspects (conceptual and measurement model,
reliability, validity, interpretability, burden of completion,
administration format, validated translations) [6].
Among these measures were the Sydney Asthma Quality
of Life Questionnaire (AQLQ-S) [7,8] and the Juniper
Asthma Quality of Life (AQLQ-J) Questionnaire [9,10].
The validation of a PROM is a continuous process as
evidence needs to accumulate to increase the confidence
in the reliability and validity of a measure. Estimates of
reliability and validity are always sample-dependent (i.e.
the coefficients obtained are expected to vary from sam-
ple to sample) [11], hence it is important to publish the
respective coefficients so a clear picture of the performance
of the questionnaires can be built up. We therefore studied
the internal consistency and validity (construct validity and
discriminative ability) of the AQLQ-S and the AQLQ-J
(mini version).
Furthermore, few studies have been conducted which
look at quality of life measures used for asthma in a
comparative manner [12-14]. This is important to get a
sense of the relative validity and conceptual structure of
PROMs which claim to measure the same thing. As a
secondary objective, we therefore compared the psycho-
metric properties of the AQLQ-S and the Mini AQLQ-J.
Methods
First, the study population was characterised by means
of descriptive statistics. Second, measures of internal
consistency were calculated for the mini AQLQ-J and
the AQLQ-S.
Third, we investigated how the two measures related to:
 each other
 symptom score lung function
 asthma control
 asthma bother
 generic quality of life
Finally, the discriminative ability of the two asthma-
specific measures with respect to age, gender, health care
utilisation (GP visits) and perceived asthma severity was
examined.
Data source
Data were drawn from the baseline assessment of a double
blind randomised controlled trial (RCT) investigating the
effects of a written emotional disclosure (WED) interven-
tion in adult patients with asthma in the UK. One hundred
fourty-six adults (18–45 years) with a diagnosis of asthma
requiring regular inhaled corticosteroids were recruited into
this trial. Participants were allocated to receive either WED
or non-emotional writing instructions and asked to write
for 20 minutes over three consecutive days. Spirometry,
health care utilisation, asthma-specific and generic quality
of life, rhinoconjunctivitis and asthma symptoms, subjective
asthma control and asthma bother were documented. The
participants’ lung function was measured using a Vitalo-
graph Micro spirometer. The remaining constructs were
assessed using self-administered questionnaires (the ques-
tionnaires were sent to participants and completed prior to
the visit by the researcher, i.e. prior to the administration of
the intervention). The questionnaires were administered in
the same order each time: Rhinoconjunctivitis and Asthma
Symptom Score, Asthma Control Test, Mini AQLQ-J,
AQLQ-S, Profile of Mood States, EuroQoL Current
Health status, Significant Other Scale and Asthma Bother
Profile. It must be noted that we used the mini version of
the AQLQ-J because this and not the original version was
included in the randomised controlled trial (RCT) from
which the data was drawn. The Profile of Mood States
and the Significant Other Scale were not considered for
this paper.
The trial was registered with www.controlled-trials.com,
registration number ISRCTN82986307. Ethical approval
was obtained from the Brighton and Mid Sussex Research
Ethics Committee (reference number 04/Q1907/91).
Quality of life measures
The AQLQ-J was developed in Canada and comprises
32 items in four domains with a two-week recall period
[9,10]. Higher ratings denote less impairment (better
quality of life). Later, a shorter and simpler questionnaire
with 15 items in the same domains was developed (Mini
AQLQ-J) [15]. There are five items in the domain
‘Symptoms’, four items in the domain ‘Activity Limita-
tions’, three items in the domain ‘Emotional Function’
and three items in the domain ‘Environmental Stimuli’.
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tionnaire showed good measurement properties, but
they were not quite as strong as for the original AQLQ-J
[15]. The minimal important difference of quality of life
score per item has been reported to be very close to 0.5
(range 0.42-0.58) for the original AQLQ-J [16].
The AQLQ-S was developed in Australia and com-
prises 20 items with a four-week recall period [7,8].
Lower ratings indicate less impairment (better quality of
life). Items are grouped into four domains (breathless-
ness: five items, mood: five items, social: seven items,
concerns: three items). The content of the question-
naires is illustrated in Table 1. For the AQLQ-S, a
minimal important difference has not been reported.
The EuroQoL Current Health Status Scale (CHS) is a
generic, preference-based measure of health status and
consists of five items (mobility, self-care, usual activities,
pain/discomfort, anxiety/depression) [17]. Higher scores
indicate better quality of life.Lung function measurement
The following parameters were measured in spirometry:
forced vital capacity (FVC) in litres [l], forced expiratory
volume in one second (FEV1) in litres [l], peak expiratory
flow (PEF) in litres per minute [l/min]. The EuropeanTable 1 Number of items and content of the AQLQ-J and the
Domain Number
of items
Content
AQLQ-J symptoms 5 Feeling short of breath as
of chest tightness or chest
of asthma, experiencing a
AQLQ-S
breathlessness
5 Having been troubled by e
attacks, having been troub
down the streets or level g
restricted in walking up hi
AQLQ-J environment 3 Feeling bothered by or ha
to avoid cigarette smoke i
because of weather or air
AQLQ-S concerns 3 Having been worried abou
having been worried abou
AQLQ-J emotions 3 Feeling frustrated as a resu
feeling concerned about h
AQLQ-S mood 3 Having felt tired or a gene
or depressed, having felt f
AQLQ-J activities 4 Having been limited in do
sports) as a result of asthm
housework, gardening, sho
doing social activities (such
been limited in doing wor
AQLQ-S social 7 Having felt that asthma is
interfered with one’s socia
bad for one’s asthma, havi
been afraid if getting an a
restricted, having been res
because of one’s asthma, h
*these should be activities which one has to do most days if not employed or self-eCoal and Steel Community (ECSC) prediction equations
were used to calculate what participant’s optimum lung
function should be based on age, height and gender
[18,19]. This reading was used with FEV1 scores to deter-
mine FEV1% predicted scores.Rhinoconjunctivitis and Asthma symptom score
The Rhinoconjunctivitis and Asthma Symptom Score has
21 items which are rated on a five point Likert scale
[20,21]. Patients are asked how much they have been dis-
turbed by symptoms during the last week. The rhinitis
module of the score asks about symptoms of irritation,
congestion and discharge in the eyes, the nose and the
sinuses. The asthma module asks about daytime and
nighttime symptoms of cough, wheeze, sputum produc-
tion and shortness of breath.Asthma Control Test (ACT)
The Asthma Control Test (ACT) consists of five questions
pertaining to the past 4 weeks [22,23]. The brief question-
naire assesses asthma symptoms (daytime and nocturnal),
use of rescue medication, and the effect of asthma on daily
functioning. The total score is obtained by summing the
scores for each item and ranges from 5 (poor control of
asthma) to 25 (complete control of asthma).AQLQ-S
a result of asthma, feeling bothered by coughing, experiencing a feeling
heaviness, having difficulty getting a good night’s sleep as a result
wheeze in the chest
pisodes of shortness of breath, having been troubled by wheezing
led by tightness in the chest, having been restricted in walking
round or doing light housework because of asthma, having been
lls or doing heavy housework because of asthma
ving to avoid dust in the environment, feeling bothered by or having
n the environment, feeling bothered or having to avoid going outside
pollution
t asthma shortening the life, having felt dependent on asthma sprays,
t present or future life because of asthma
lt of asthma, feeling afraid of not having asthma medication available,
aving asthma
ral lack of energy, having been unable to sleep at night, having felt sad
rustrated with oneself, having felt anxious, under tension or stressed
ing strenuous activities (such as hurrying, exercising, running up chairs,
a, having been limited in doing moderate activities (such as walking,
pping, climbing stairs) as a result of asthma, having been limited in
as talking, playing with pets/children, visiting friends/relatives), having
k-related activities* (tasks you have to do at work)
preventing one from achieving what one wants in life, asthma having
l life, having been limited in going to certain places because they are
ng been limited in going to certain places because of having
sthma attack and not being able to get help, having felt generally
tricted in the sports, hobbies, or other recreations one can engage in
aving felt asthma is controlling one’s life
mployed.
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The Asthma Bother Profile (ABP) is a 15 item measure
of asthma distress [24]. Patients are asked how much
their asthma bothers them in the different areas of their
life and they are given six response options (no bother,
minor irritation, slight bother, moderate bother, a lot of
bother, makes my life a misery) and one ‘not applicable’
option. Higher scores indicate greater distress.
Statistical analysis
To describe the characteristics of the sample, counts and
percent were calculated for categorical variables and
means with standard deviations (SD) were calculated for
continuous variables.
In order to analyse the distribution of domain and
total scores for the two asthma-specific quality of life
measures mean, median, standard deviation (SD), per-
centage of participants with missing items, observed
range, the percentage of participants with the worst pos-
sible score (‘floor’) and percentage of participants with
the best possible score (‘ceiling’) were calculated. Stan-
dardized Cronbach’s alpha coefficients were computed
as a measure of internal consistency [25].
Correlational analyses were performed to analyse the
relationship between scores where appropriate. Spear-
man rank-order correlations, non-parametric measures
of association based on the ranks of the data values, were
calculated because the scores of the measures of interest
(AQLQ-J and AQLQ-S) were not normally distributed.
In order to analyse the relationship between the domain
and total scores of the AQLQ-J and the AQLQ-S, a correl-
ation matrix was computed. Correlations were considered
as absent if rho < 0.20, poor if rho= 0.20 <= rho<= 0.34,Table 2 Distribution of scores and internal consistency of AQ
AQLQ-J
Symptoms Environmental
Stimuli
Emotional
Function
Activity
Limitation
Items [n] 5 3 3 4
Mean 5.06 5.38 5.18 5.97
Median 5.20 5.67 5.33 6.25
SD 1.15 1.24 1.48 1.12
Participants
with missing
items [%]
4.79 4.79 5.48 5.48
Theoretical
range
1-7 1-7 1-7 1-7
Observed
range
1.80-7.00 1.33-7.00 1.00-7.00 1.50-7.00
‘Floor’ [%]* 0 0 1.45 0
‘Ceiling’ [%]** 1.44 10.79 10.87 25.36
Cronbach’s
alpha
0.85
(N=139)
0.61
(N=139)
0.82
(N=138)
0.89
(N=138)
*Percentage of participants with worst possible score.
**Percentage of patients with best possible score.moderate if rho= 0.35 <= rho <=0.50 and strong if rho >
0.50 [26]. In order to compare scores between categories
(gender, GP visits, perceived severity), non-parametric
tests were used (Wilcoxon rank sum two sample test for
comparison between two groups and Kruskal-Wallis test
for comparison between more than two groups). Missing
data in the questionnaires were dealt with by imputing
mean values where more than half of the responses to a
subscale were present.
All analyses were performed using SAS 9.2 for Windows.Results
Patient characteristics
One hundred fourty-six people with asthma (average
disease duration: 21.4 years (SD: 11.5 years)), aged 18–
45 years and with a mean age of 36.1 years (SD:
7.0 years), participated in the study. Most of the partici-
pants were female (76.7%), in employment (82.2%) and
of white ethnicity (97.3%). Their asthma was perceived
as mild by 48.0%, as moderate by 45.9% and as severe by
3.4%. About one quarter (25.3%) of all patients reported
consulting their general practitioner because of their
asthma during the past four months (excluding asthma
review appointments), 3.4% reported they had visited
Accident & Emergency (A&E) because of their asthma
during the past four months but none reported having
been admitted to hospital in the same time period.
The distribution of the questionnaire scores is dis-
played in Table 2. The mean AQLQ-J score was 5.4 (SD:
1.0, minimum 1.7, maximum 7.0), the mean AQLQ-S
was 0.8 (SD 0.6, minimum 0.1, maximum 3.4). About
one quarter of the responses in the ‘activity limitation’LQ-J and AQLQ-S
AQLQ-S
Total Breathlessness Mood Social Concerns Total
15 5 5 7 3 20
5.39 0.83 0.99 0.52 0.76 0.80
5.60 0.60 0.80 0.29 0.57 0.70
1.04 0.60 0.76 0.68 0.66 0.58
6.16 5.48 5.48 4.79 5.48 5.48
1-7 0-4 0-4 0-4 0-4 0-4
1.67-7.00 0-3.00 0-3.80 0-4.00 0-3.57 0.05-3.35
0 0 0 0 0 0
0.73 5.80 10.90 26.62 12.32 0
0.92
(N=137)
0.83
(N=138)
0.85
(N=138)
0.91
(N=139)
0.77
(N=139)
0.93
(N=138)
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AQLQ-S were the best possible scores (ceiling effect).
Mean rhinoconjunctivitis and asthma symptom score
was 45.2 (SD: 13.9, median: 44.5, range: 20.0-89.0,
N= 136). For the asthma module, mean symptom score
was 20.4 (SD: 7.6, median: 19.0, range: 9.0 - 42.0,
N= 137) and for the rhinitis module, mean symptom
score was 24.8 (SD: 8.1, median: 25.0, range: 11.0-48.0,
N= 136).
The following spirometry results were observed
(N= 145): mean FVC was 3.72 l (SD 1.03, range: 1.37-
7.35), mean FEV1 was 2.82 l (SD 0.77, range: 0.74-4.95),
mean FEV1, % predicted was 87.5% (SD: 20.5, range:
24.8 - 167.3) and mean PEF was 427.4 l/min (SD: 132.2,
range: 117.0-847.0).
Internal consistency
Cronbach’s alpha values for the total and the domain
scores of both QoL measures are also displayed in
Table 2.
For the subscales of the AQLQ-J, all Cronbach’s alpha
values were >= 0.61 and for the subscales of the AQLQ-S,
all Cronbach’s alpha values were >= 0.83. Cronbach’s alpha
was 0.92 for the total AQLQ-J score and 0.93 for the total
AQLQ-S score.
Correlation of AQLQ-J and AQLQ-S
A correlation matrix of the two measures is shown in
Table 3. The total scores of the AQLQ-J and AQLQ-S
correlated strongly with each other (rho=−0.80,
p < 0.0001). The domain scores of the AQLQ-J and
AQLQ-S showed weaker, but still strong (0.50 < = rho < =
0.80) correlations with each other. The only exceptionTable 3 Relationship of domain and total scores of AQLQ-J an
AQLQ-J
Symptoms Environmental
Stimuli
Emotional
Function
Activ
Limi
AQLQ-J
Symptoms - 0.54 0.68 0.60
Environmental
Stimuli
- 0.52 0.47
Emotional Function 0.52 -
Activity Limitation 0.47 0.51 -
Total
AQLQ-S
Breathlessness -0.74 -0.42 -0.54 -0.61
Mood -0.57 -0.36 -0.46 -0.42
Social -0.52 -0.54 -0.53 -0.70
Concerns -0.59 -0.45 -0.65 -0.53
Total -0.73 -0.52 -0.66 -0.66
Spearman’s rank correlation coefficients, all correlation coefficients showed p values
Correlations between AQLQ-J and AQLQ-S scores are negative because the respectwas the ‘mood’ domain of the AQLQ-S which correlated
moderately (rho < 0.5) with the ‘environmental stimuli’,
the ‘emotional function’ and the ‘activity limitation’ do-
main of the AQLQ-J.
Correlation of AQLQ-J and AQLQ-S with
Rhinoconjunctivitis and Asthma Symptom Score
Both QoL measures were significantly correlated with the
Rhinoconjunctivitis and Asthma Symptom Score, but the
correlation of the AQLQ-J with the symptom score was
stronger (rho=−0.62, p < 0.0001, N=134) compared with
the correlation of the AQLQ-S (rho= 0.46, p < 0.0001,
N=135). For both QoL measures, correlations with the
symptom score asthma module (AQLQ-J: rho=−0.69,
p< 0.0001, N=135; AQLQ-S: rho= 0.50, p < 0.0001,
N=136) were stronger compared with the total symptom
score and the symptom score rhinitis module (AQLQ-J:
rho=−0.41, p < 0.0001, N=134; AQLQ-S: rho= 0.31,
p= 0.0002, N= 135).
Correlation of AQLQ-J and AQLQ-S with lung function
As shown in Table 4, the AQLQ-J total score and all do-
main scores except ‘emotional function’ were significantly
correlated with FVC, but only the association with en-
vironmental stimuli was of moderate strength. Regard-
ing the AQLQ-S, a significant, but weak correlation with
FVC was found for the ‘breathlessness’ domain. The
AQLQ-J total score and the domains ‘environmental stim-
uli’ as well as ‘activity limitation’ showed significant, but
weak correlations with FEV1 and PEF.
Neither the total score nor any domain score of the
AQLQ-S were significantly correlated with FEV1. There
were, however, significant correlations of the AQLQ-Sd AQLQ-S (correlation matrix)
AQLQ-S
ity
tation
Total Breathlessness Mood Social Concerns Total
0.90
0.73
0.82
0.78
-
-0.72 -
-0.58 0.57 -
-0.68 0.56 0.41 -
-0.68 0.59 0.61 0.68 -
-0.80 0.81 0.80 0.76 0.88
< 0.0001.
ive scores run in opposite directions.
Table 4 Relationship of spirometry parameters with domain and total scores of AQLQ-J and AQLQ-S
AQLQ-J AQLQ-S
Symptoms
(N=138)
Environmental
Stimuli
(N=138)
Emotional
Function
(N=137)
Activity
Limitation
(N=137)
Total
(N=136)
Breathlessness
(N=137)
Mood
(N=137)
Social
(N=138)
Concerns
(N=137)
Total
(N=137)
FVC 0.24
(p=0.005)
0.36
(p<0.0001)
0.17
(p=0.05)
0.33
(p<0.0001)
0.33
(p<0.0001)
-0.22
(p=0.01)
-0.12
(p=0.15)
-0.16
(p=0.05)
-0.11
(p=0.19)
-0.17
(p=0.05)
FEV1 0.15
(p=0.07)
0.20
(p=0.02)
0.08
(p=0.38)
0.23
(p=0.007)
0.20
(p=0.02)
-0.16
(p=0.07)
-0.05
(p=0.56)
-0.07
(p=0.39)
-0.06
(p=0.50)
-0.09
(p=0.31)
PEF 0.13
(p=0.13)
0.26
(p=0.002)
0.12
(p=0.17)
0.32
(p=0.0001)
0.24
(p=0.006)
-0.18
(p=0.04)
-0.09
(p=0.32)
-0.22
(p=0.01)
-0.09
(p=0.32)
-0.14
(p=0.09)
FEV1, %
predicted
0.15
(p=0.08)
0.09
(p=0.32)
0.10
(p=0.25)
0.17
(p=0.05)
0.16
(p=0.06)
-0.17
(p=0.05)
-0.01
(p=0.88)
-0.09
(0.31)
-0.10
(p=0.26)
-0.09
(p=0.29)
Spearman’s rank correlation coefficients.
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relation with ‘breathlessness’ qualified as absent, while
the correlation with ‘social’ classified as weak. No signifi-
cant correlation of either QoL measure at total or do-
main level was observed with FEV1, % predicted.
Correlation of AQLQ-J and AQLQ-S with asthma control
Both AQLQ-J total score (rho=0.68, p< 0.0001, N=136)
and AQLQ-S total score (rho=−0.61, p < 0.0001, N=137)
were significantly correlated with asthma control.
Correlation of AQLQ-J and AQLQ-S with Asthma Bother
Profile (ABP)
Both QoL measures correlated significantly with the ABP
to the same degree (AQLQ-J: rho=−0.73, p < 0.0001,
N= 130; AQLQ-S: rho=0.73, p< 0.0001, N=131).
Correlation of AQLQ-J and AQLQ-S with EuroQoL current
health status (CHS)
Both AQLQ-J (rho=0.35, p<0.0001, N=134) and the
AQLQ-S (rho=−0.40, p<0.0001, N=135) correlated signifi-
cantly with the EuroQoL Current Health Status Scale (CHS).
Relationship of AQLQ-J and AQLQ-S to patient
characteristics (age, gender, GP visits, perceived asthma
severity)
Neither measure correlated with age (rho= 0.01, p= 0.92,
N= 137 for the AQLQ-J and rho=−0.03, p= 0.77,
N= 138 for the AQLQ-S). As shown in Table 5, there
was no significant difference between male and female
in total AQLQ-J scores, but a significantly better QoL
score was observed in the male group for the domains
‘environmental stimuli’ and ‘activity limitation’. No sig-
nificant difference between male and female was
observed for the AQLQ-S total and in the domains.
Scores were significantly worse for those patients who
reported having visited their GP during the past four
months for the AQLQ-J total and the ‘symptom’ and ‘ac-
tivity limitation’ domains. They were also significantlyworse for the AQLQ-S total as well as the ‘breathless-
ness’ , ‘mood’ and ‘concerns’ domains.
The relationship between median quality of life scores
and perceived asthma severity was significant for the
‘symptoms’ and ‘emotional function’ domain scores of
the AQLQ-J as well as the total AQLQ-J score. The rela-
tionship between median quality of life scores and per-
ceived asthma severity was also significant for the
‘breathlessness’, ‘mood’, ‘concerns’ domains and the total
score of the AQLQ-S.
Discussion
Overall, we observed mild quality of life impairment in
our sample of adult patients with asthma recruited in
Southern England, as measured by the mini version of
the Juniper Asthma Quality of Life Questionnaire
(AQLQ-J) and the Marks Asthma Quality of Life Ques-
tionnaire (AQLQ-S). Like in a previous Dutch study
[13], this may be explained by the fact that all patients
were recruited through primary care.
Missing item-level data were imputed as the mean of
at least 50% of the subscale items. Ordinarily this might
be expected to reduce the precision of calculated statis-
tics. However, in this context imputation of values from
at least 50% of subscale items is acceptable, since the
subscale items were highly correlated with each other (as
should be expected for items on a common subscale).
Hence it was reasonable to infer a given missing item
value from the mean value of the completed items. In
fact, the highest percentage of missing data among all
the scales used was 9.6% for the Asthma Bother Profile.
We found acceptable internal consistency (α > 0.7) for
both asthma-specific quality of life measures at total and
domain level, except for the ‘environmental stimuli’ do-
main of the AQLQ-J.
Both measures correlated strongly with each other at
the total score level. This was also true for most
domain-domain correlations. Similarly strong domain-
domain and domain-total as well as total-total correla-
tions were found in a Spanish study which compared the
Table 5 Median score (interquartile range) of AQLQ-J and AQLQ-S according to patient characteristics
AQLQ-J AQLQ-S
Symptoms Environmental
Stimuli
Emotional
Function
Activity
Limitation
Total Breathlessness Mood Social Concerns Total
Gender
Female 5.20 (4.20-6.00)
N=105
5.67 (4.67-6.00)
N=105
5.33 (4.00-6.33)
N=105
6.25 (5.25-6.75)
N=104
5.50 (4.57-6.07)
N=104
0.80 (0.40-1.20)
N=104
0.80 (0.40-1.40)
N=104
0.29 (0.00-0.86)
N=105
0.57 (0.29-1.14)
N=104
0.70 (0.35-1.10)
N=104
Male 5.10 (4.60-6.00)
N=34
6.00 (5.33-7.00)
N=34
5.67 (4.33-6.33)
N=33
6.63 (5.75-7.00)
N=34
5.93 (5.27-6.20)
N=33
0.60 (0.40-1.00)
N=34
0.90 (0.40-1.40
N=34
0.14 (0.00-0.71)
N=34
0.64 (0.29-1.00)
N=34
0.63 (0.45-0.95)
N=34
P value* 0.58 0.003 0.61 0.03 0.10 0.48 0.70 0.39 0.74 0.69
Health care usage (GP visit) during the past four months
Yes 4.20 (3.60-5.20)
N=35
5.33 (4.00-6.00)
N=35
5.00 (4.00-6.33)
N=35
6.00 (4.25-6.75)
N=35
4.93 (4.40-5.93)
N=35
1.00 (0.60-1.60)
N=35
1.20 (0.80-1.80)
N=35
0.29 (0.00-1.29)
N=35
0.86 (0.43-1.43)
N=35
0.90 (0.55-1.55)
N=35
No 5.40 (4.60-6.10)
N=104
5.67 (4.67-6.33)
N=104
5.67 (4.33-6.67)
N=103
6.25 (5.75-7.00)
N=103
5.77 (5.13-6.20)
N=102
0.60 (0.40-1.00)
N=103
0.80 (0.40-1.20)
N=103
0.29 (0.07-0.71)
N=104
0.57 (0.29-1.00)
N=103
0.55 (0.35-0.95)
N=103
P value* 0.0009 0.05 0.09 0.04 0.003 0.002 0.0003 0.51 0.01 0.002
Perceived asthma severity
No
symptoms
6.10 (5.40-6.20)
N=4
6.00 (5.50-6.50)
N=4
6.00 (5.50-6.67)
N=4
6.88 (6.38-7.00)
N=4
6.27 (5.73-6.53)
N=4
0.30 (0.20-0.50)
N=4
0.40 (0.10-0.70)
N=4
0.14 (0.07-0.50)
N=4
0.00 (0.00-0.43)
N=4
0.23 (0.15-0.48)
N=4
Mild 5.40 (4.60-6.20)
N=67
5.67 (4.67-6.00)
N=67
6.00 (4.67-6.67)
N=67
6.50 (6.00-7.00)
N=66
5.80 (5.20-6.33)
N=66
0.60 (0.40-0.80)
N=66
0.80 (0.40-1.20)
N=66
0.14 (0.00-0.71)
N=67
0.43 (0.29-1.00)
N=66
0.53 (0.35-0.90)
N=66
Moderate 5.00 (3.90-5.80)
N=64
5.67 (4.67-6.33)
N=64
5.00 (4.00-6.00)
N=63
6.25 (5.13-6.75)
N=64
5.33 (4.53-5.93)
N=63
0.80 (0.60-1.40)
N=64
0.98 (0.50-1.40)
N=64
0.29 (0.00-0.86)
N=64
0.71 (0.43-1.21)
N=64
0.73 (0.45-1.28)
N=64
Severe 3.50 (2.60-4.10)
N=4
4.17 (2.67-5.33)
N=4
3.50 (2.17-5.33)
N=4
4.50 (3.63-5.88)
N=4
4.20 (2.93-4.93)
N=4
1.70 (1.30-2.20)
N=4
1.70 (1.60-2.80)
N=4
1.38 (0.29-2.93)
N=4
1.43 (0.71-2.79)
N=4
1.58 (1.03-2.65)
N=4
P value** 0.003 0.28 0.01 0.05 0.004 0.0002 0.007 0.29 0.008 0.002
*Wilcoxon rank sum two sample test (normal approximation, including continuity correction).
**Kruskal-Wallis test.
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St George’s Respiratory Questionnaire (SGRQ) [27].
Correlations with the symptom score, particularly the
asthma module of the symptom score, were strong for
the AQLQ-J and moderate for the AQLQ-S.
The strength of the correlation of the AQLQ-J (rho=
0.69) with asthma symptoms we found was comparable
to that found in the Dutch study (rho= 0.65) [13]. Taking
the perspective of van der Molen et al. [13] this may be
interpreted as evidence for (cross-sectional) construct
validity, although we have taken the stance before that
not symptoms per se, but the impact of symptoms is in-
fluencing asthma-specific quality of life [6]. Hence, the
strong correlation of the AQLQ-J with the symptom
score may raise the question of overlap between the
symptom score construct and the quality of life con-
struct as operationalized in the AQLQ-J.
The stronger correlation of the AQLQ-J compared to
the AQLQ-S with the symptom score seems plausible in
the light of the fact that the AQLQ-J has more
symptom-related items compared to the AQLQ-S.
The finding that correlations of both measures (at
total and domain level) with lung function measures
were weak, if not absent, was expected. It corroborates
previous findings [13,14].
The AQLQ-J showed more and stronger correlations
with lung function measures. This was expected because
the AQLQ-J has more symptom-based items. The find-
ings for lung function contrasted with the strong corre-
lations found for asthma bother and asthma control.
Taking the moderate strength of the correlations with
generic quality of life into account, we interpret the find-
ings from these correlational analyses as supporting evi-
dence for construct validity of both measures.
The relationships of the AQLQ-J and AQLQ-S with
health care utilization as measured by GP visits and with
perceived asthma severity were as expected and support
the discriminative ability of both measures. The observed
gender difference is less clear. There are few studies look-
ing into gender differences in asthma-specific quality of
life. A very recent study from India found that women
reported poorer quality of life, especially in the symptoms
and emotional domains of the AQLQ [28]. The findings
point in a similar direction to our findings, however we
found significant differences in the “environmental stim-
uli” and “activity limitation” domains.
Conclusions
This study provides evidence for the validity of the mini
AQLQ-J and the AQLQ-S in a British population of
adults with asthma who are managed in primary care.
The correlations with lung function and symptoms were
different for the two measures and stronger for the mini
AQLQ-J compared to the AQLQ-S, reflecting partly thedifferent content of the questionnaires. Both the mini
AQLQ-J and the AQLQ-S are able to discriminate be-
tween patients with differing levels of asthma severity.
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